To overcome two diseases with one pill

Hypertension Research

Volumn 39, Issue 6, 2016, Pages 399-400

  Mogi, Masaki ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; NORADRENALIN; PLACEBO;

ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; ARTERIAL STIFFNESS; BLOOD VESSEL TONE; CIRCADIAN RHYTHM; DIABETIC PATIENT; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HIGH SODIUM INTAKE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; MEAN ARTERIAL PRESSURE; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; NOTE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; SLEEP TIME; SODIUM EXCRETION; SODIUM URINE LEVEL; SYMPATHETIC NERVE CELL; WATER RETENTION; ATTITUDE TO HEALTH;

HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS;

EID: 84974716096     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2016.3     Document Type: Note

References (15)

1. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420-428.
2. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128.
3. Takeshige Y, Fujisawa Y, Rahman A, Kittikulsuth W, Nakano D, Mori H, Masaki T, Ohmori K, Kohno M, Ogata H, Nishiyama A. A sodium-glucose co-transporter 2. inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Hypertens Res 2016; 39: 415-422.
4. Yano Y, Kario K. Nocturnal blood pressure and cardiovascular disease: A review of recent advances. Hypertens Res 2012; 35: 695-701.
5. Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian rhythm of blood pressure: The keys to connect CKD with cardiovascular events. Hypertens Res 2010; 33: 515-520.
6. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol 2014; 13: 148.
7. Rafiq K, Fujisawa Y, Sherajee SJ, Rahman A, Sufiun A, Kobori H, Koepsell H, Mogi M, Horiuchi M, Nishiyama A. Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia 2015; 58: 2885-2898.
8. Kim EJ, Lee YJ, Lee JH, Han HJ. Effect of epinephrine on alpha-methyl-D-glucopyranoside uptake in renal proximal tubule cells. Cell Physiol Biochem 2004; 14: 395-406.
9. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13: 28.
10. Takatori S, Fujiwara H, Zamami Y, Hashikawa-Hobara N, Kawasaki H. Decreased perivascular CGRP-containing nerves in Otsuka Long-Evans Tokushima Fatty rats with insulin resistance and hypertension. Hypertens Res 2014; 37: 398-404.
11. Leu HB, Chung CM, Lin SJ, Chiang KM, Yang HC, Ho HY, Ting CT, Lin TH, Sheu SH, Tsai WC, Chen JH, Yin WH, Chiu TY, Chen CI, Fann CS, Chen YT, Pan WH, Chen JW. Association of circadian genes with diurnal blood pressure changes and non-dipper essential hypertension: A genetic association with young-onset hypertension. Hypertens Res 2015; 38: 155-162.
12. Gumz ML, Stow LR, Lynch IJ, Greenlee MM, Rudin A, Cain BD, Weaver DR, Wingo CS. The circadian clock protein Period 1 regulates expression of the renal epithelial sodium channel in mice. J Clin Invest 2009; 119: 2423-2434.
13. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G, Kanematsu A, Ogawa O, Todo T, Tsutsui K, van der Horst GT, Okamura H. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med 2010; 16: 67-74.
14. Kovanen L, Donner K, Kaunisto M, Partonen T. Cry1, Cry2 and PRKCDBP genetic variants in metabolic syndrome. Hypertens Res 2015; 38: 186-192.
15. Shin S, Song H, Oh SK, Choi KE, Kim H, Jang S. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients. Hypertens Res 2013; 36: 1000-1005.